Add BrightSurf on Google Email

Expert panel compares opioid epidemic to early days of HIV epidemic

An expert panel has identified parallels between the current opioid epidemic and the early days of the HIV epidemic. The panel recommends five crucial steps for clinicians treating patients affected by opioid addiction and these intersecting infections, including increasing access to addiction care and developing hospital-based protocols.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·DateJul 13, 2018

Preventative HIV vaccine candidate triggers desired immune responses in humans and monkeys, and protects monkeys from infection

A new HIV vaccine candidate has triggered desired immune responses in humans and monkeys, demonstrating robust protection against infection. The 'mosaic' vaccine contains a patchwork of genetic sequences found among various HIV strains, providing broad protection against the many strains prevalent worldwide.

Cost-effective universal screening for hepatitis C in France

A mathematical model developed by Sylvie Deuffic-Burban assesses the efficacy and cost-effectiveness of different screening strategies, including universal screening. The results show that universal screening is associated with better life expectancy adjusted for quality of life than other strategies.

SourceANRS·JournalJournal of Hepatology·DateJul 1, 2018

New simulation tool predicts how well HIV-prophylaxis will work

A new mathematical framework predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, helping streamline the development of new treatments. The framework integrates molecular factors that affect drug efficacy, allowing researchers to evaluate clinical efficacy prior to clinical trials.

SourcePLOS·JournalPLOS Computational Biology·DateJun 14, 2018

Many at risk for HIV despite lifesaving pill

A new University of Michigan study reveals that high-risk individuals face multiple barriers to accessing pre-exposure prophylaxis (PrEP), a lifesaving HIV drug. The researchers outline 31 potential solutions to overcome these barriers, which affect patient, provider, and health-system levels.

SourceUniversity of Michigan·JournalAIDS and Behavior·DateJun 11, 2018

A 'super' receptor that helps kill HIV infected cells

Monash researchers have discovered a unique set of 'super' receptors on immune cells capable of killing HIV across genetically diverse populations. These killer CD4+ T cells can recognize HIV fragments in people with different HLA molecules, a feature that may help control the spread of the disease.

SourceMonash University·JournalScience Immunology·DateJun 8, 2018

HIV study reveals new group of men at risk of infection

A new study has identified a distinct group of men who may be underestimating their HIV risk due to fear of stigma and rejection. These men, including bisexual and non-gay-identified individuals, tend to mix with each other and acquire infection from within their own networks, rather than openly gay men or heterosexual women.

SourceUniversity of Edinburgh·JournalThe Lancet HIV·DateJun 4, 2018

Genome editing method targets AIDS virus

A Japanese research group has developed a CRISPR/Cas9 system to target and block HIV-1 production in infected cells. By targeting two regulatory genes tat and rev, they were able to significantly lower the expression and functions of both genes.

SourceKobe University·JournalScientific Reports·DateMay 18, 2018

La Trobe's infection-busting discovery

A team of La Trobe University scientists has discovered a peptide found in the flowers of the ornamental tobacco plant Nicotiana alata that can target and destroy Candida albicans cells, making it a promising lead for developing a new class of antibiotics.

SourceLa Trobe University·JournalNature Communications·DateMay 17, 2018

Watch how a T cell passes HIV sexually to a new host

Researchers have developed an in vitro model of urethral mucosa to visualize the HIV transmission process. The study reveals that infected T cells target epithelial cells above macrophages, leading to viral production and shedding via transcytosis. Macrophages then capture and store the virus, posing a challenge for treatment efforts.

SourceCell Press·JournalCell Reports·DateMay 8, 2018

Early HIV treatment key to avoiding brain atrophy

A new study suggests that early HIV treatment can prevent brain atrophy and cognitive decline, emphasizing the importance of timely antiretroviral therapy. By analyzing MRI data from patients with early HIV infection, researchers found that cART treatment halted volume loss and cortical thinning in several brain regions.

SourceMcGill University·JournalClinical Infectious Diseases·DateMay 3, 2018

The fewer the deadlier

Researchers discovered that HTLV-1 survives by evading immune surveillance through transient Tax expression in infected cells. This unique strategy allows the virus to maintain a population of infected leukemic cells, making it a potential target for new therapies.

SourceKyoto University·JournalProceedings of the National Academy of Sciences·DateApr 12, 2018

Peer influence, better HIV counseling could encourage boys in Africa to be circumcised

A recent study found that a focus on boys and young men is crucial to continue progress in reducing new HIV infections. Researchers suggest that improved health counseling and engagement with peers can encourage more adolescents to undergo circumcision, which reduces the risk of HIV transmission by 60%. The study also highlights the ne...

SourceJohns Hopkins Bloomberg School of Public Health·JournalClinical Infectious Diseases·DateApr 3, 2018

The Lancet Gastroenterology & Hepatology: Almost 300 million people have hepatitis B virus worldwide, but just 1 in 20 of those eligible receive treatment

The study highlights the significant burden of hepatitis B virus globally, with 292 million individuals living with the virus in 2016. Only 5% of eligible patients received antiviral therapy, and less than 1% of expectant mothers with high viral load received prophylaxis to prevent mother-to-child transmission.

SourceThe Lancet·JournalThe Lancet Gastroenterology & Hepatology·DateMar 26, 2018